Logo Logo

Publications by Assmann, M.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Jump to: 2017 | 2016
Number of items: 3.

2017

Lange, T.; Krahl, R.; Grünhagen, U. von; Al-Ali, H. K.; Schwarzer, A.; Jentsch-Ullrich, K.; Spohn, C.; Lakner, V.; Assmann, M.; Junghanss, C.; Pfirrmann, M.; Gil, A.; Hehlmann, R.; Deininger, M.; Niederwieser, D. (2017): Imatinib (IM) in combination with Hydroxyurea in patients with CML1st CP does not increase molecular response at 18 months compared to IM alone. Final results of the OSHO CML2004 study. NCT 02480608. In: Oncology Research and Treatment, Vol. 40: pp. 121-122

Lange, T.; Krahl, R.; Grünhagen, U. vom; Al-Ali, H. K.; Schwarzer, A.; Uhle, R.; Spohn, C.; Lakner, V.; Assmann, M.; Junghanss, C.; Pfirrmann, M.; Gil, A.; Hehlmann, R.; Deininger, M.; Niederwieser, D. (2017): Imatinib (im) 400mg in patients with cml1st cp results in a higher molecular response rate at 6 months compared to im/hydroxyurea. Final results of the cml2004 study. Nct 02480608. In: Haematologica, Vol. 102: pp. 729-730

2016

Hecht, M.; Hahn, D.; Beutner, D.; Reichert, D.; Göhler, T.; Wurm, R.; Welslau, M.; Renziehausen, L.; Balermpas, P.; Bergmann, T.; Assmann, M.; Belka, C.; Orlowski, K.; Finzsch, M.; Illerhaus, G.; Fietkau, R. (2016): Cetuximab in combination with platinum-based chemotherapy or radiotherapy in recurent and/or metastatic SCCHN in a non-selected patient cohort (interim analysis of the phase IV SOCCER trial). In: Annals of Oncology, Vol. 27

This list was generated on Sat Nov 28 00:51:40 2020 CET.